Menu
Search
|

Menu

Close
X

Eagle Pharmaceuticals Inc EGRX.OQ (NASDAQ Stock Exchange Global Market)

49.48 USD
-- (--)
As of Nov 14
chart
Previous Close 49.48
Open --
Volume --
3m Avg Volume 92,830
Today’s High --
Today’s Low --
52 Week High 85.66
52 Week Low 46.88
Shares Outstanding (mil) 14.91
Market Capitalization (mil) 754.76
Forward P/E 24.70
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
157
FY17
237
FY16
189
FY15
36
EPS (USD)
FY18
1.248
FY17
3.478
FY16
4.995
FY15
-1.497
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
24.70
29.53
Price to Sales (TTM)
vs sector
3.70
22.95
Price to Book (MRQ)
vs sector
3.89
4.15
Price to Cash Flow (TTM)
vs sector
21.21
20.94
Total Debt to Equity (MRQ)
vs sector
22.83
15.47
LT Debt to Equity (MRQ)
vs sector
20.26
11.13
Return on Investment (TTM)
vs sector
13.65
13.00
Return on Equity (TTM)
vs sector
17.42
14.69

EXECUTIVE LEADERSHIP

Michael Graves
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
David Pernock
President, Chief Operating Officer, Since 2018
Salary: $515,000.00
Bonus: $216,000.00
Scott Tarriff
Chief Executive Officer, Director, Since 2017
Salary: $747,000.00
Bonus: $523,000.00
Pete Meyers
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Since 2017
Salary: $238,465.00
Bonus: $112,000.00
Adrian Hepner
Executive Vice President, Chief Medical Officer, Since 2016
Salary: $412,000.00
Bonus: $136,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

50 Tice Blvd Ste 315
WOODCLIFF LAKE   NJ   07677-7637

Phone: +1201.3265300

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

SPONSORED STORIES